90718951 - HELA 3.0

Information

• Trademark
• 90718951

• Source

• Serial Number

  90718951

• International Classifications

  • 1 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry
  • 42 - Scientific and technological services and research and design relating thereto
  • 44 - Medical services
  • 45 - Legal services

• Filing Date

  May 18, 2021
  3 years ago

• Transaction Date

  October 13, 2022
  a year ago

• Status Date

  October 13, 2022
  a year ago

• Location Date

  October 13, 2022
  a year ago

• Status Code

  602

• Current Location

  TMO LAW OFFICE 303- EXAMINING ATTORNEY ASSIGNED

  Employee Name

  BAYLESS-DAVIS, MARIAH

• Attorney Docket Number

  315613-20000

  Attorney Name

  Anne H. Peck

  Law Office Assigned Location Code

  T40

• Owners

  • ULTRAGENYX PHARMACEUTICAL INC.

Case File Statements

• PM0001: HELA THREE POINT ZERO; HEAL THREE ZERO
• GS0011: Chemical, biological, and biochemical products for use in gene delivery technology, namely, nucleic acids, including coding and non-coding deoxyribonucleic acids, plasmids, vectors, promotors, enhancers and other regulatory sequences, for in vitro laboratory use and in vivo therapeutic use in gene therapy; chemical, biological, and biochemical products for use in the manufacture of pharmaceutical preparations
• GS0451: Licensing of intellectual property
• GS0441: Providing medical services, namely, gene therapy design and delivery services being gene therapy medical services in the field of genetic diseases and disorders; providing medical services, namely, gene therapy design and delivery services being gene therapy medical services in the field of liver, hepatological, cardiovascular, central nervous system, endocrine, inflammatory, metabolic, autoimmune, musculoskeletal, neurological, ophthalmologic, respiratory, and hematologic diseases and disorders; medical information services in the nature of providing a database in the field of gene therapy information based on collected patient data and information all for treatment and diagnostic purposes; medical information services
• GS0421: Research and development in the field of gene therapy manufacturing technology; biomedical and scientific research in the fields of genome editing, gene editing, genome engineering, gene modulation, genetic diseases, gene therapy, and cell therapy; product development in the fields of genetic therapies and effectors to regulate, modulate, and characterize disease states; pharmaceutical research and development in the field of gene therapy; conducting clinical trials for others in the field of gene therapy design and delivery; biomedical research in the field of gene therapy design and delivery; gene therapy design and delivery development of biochemical assays; compiling and sharing of patient data for research purposes in the field of medical science

Case File Event Statements

• 10/13/2022 - a year ago

  9 - ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND Type: MAB2

• 10/13/2022 - a year ago

  8 - ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND Type: MAB2

• 10/13/2022 - a year ago

  7 - ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE Type: ABN2

• 3/31/2022 - 2 years ago

  6 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN

• 3/31/2022 - 2 years ago

  5 - NON-FINAL ACTION E-MAILED Type: GNRT

• 3/31/2022 - 2 years ago

  4 - NON-FINAL ACTION WRITTEN Type: CNRT

• 1/27/2022 - 2 years ago

  3 - ASSIGNED TO EXAMINER Type: DOCK

• 8/16/2021 - 2 years ago

  2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM Type: NWOS

• 5/21/2021 - 3 years ago

  1 - NEW APPLICATION ENTERED IN TRAM Type: NWAP